<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00134784</url>
  </required_header>
  <id_info>
    <org_study_id>Elldopa</org_study_id>
    <nct_id>NCT00134784</nct_id>
  </id_info>
  <brief_title>Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression</brief_title>
  <acronym>ELLDOPA</acronym>
  <official_title>[123I]ß-CIT and SPECT in Vivo Three Year Imaging Assessment of Dopamine Transporter Density in Subjects With Early Parkinson's Disease Participating in Earlier vs. Later Levodopa in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute for Neurodegenerative Disorders</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute for Neurodegenerative Disorders</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this project is to assess the change in dopamine transporter density in
      Parkinson's disease subjects during a sixty month period including a nine month treatment
      trial of levodopa. Dopamine transporter will be assessed using [123I]ß-CIT SPECT (single
      photon emission computed tomography) imaging, a marker of dopamine terminal integrity and of
      clinical disease state.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects will be imaged at the Institute for Neurodegenerative Disorders.

      Subjects will be evaluated sequentially with [123I]ß-CIT SPECT and standardized clinical
      rating scales during a sixty month period. The subjects involved in this study will have had
      [123I]ß-CIT and SPECT scans at baseline and return for scanning at week 40 following the
      start of their participation in the ELLDOPA study.

      Before each SPECT procedure subjects will be tested to ensure eligibility for the study. They
      will also have a neurological evaluation including tests of motor function, thinking, memory
      and handwriting. Some of these tests will be given with the aid of a computer.

      On the first day participants are injected with [123I]ß-CIT, an investigational radioactive
      material that localizes in the brain. Study participants will also have a thorough neurologic
      examination and standard neuropsychological testing, including testing of memory,
      concentration, abstraction and visual spatial functions.

      Twenty-four hours later study participants return to the Institute for Neurodegenerative
      Disorders where an investigational scanning procedure will be used to obtain SPECT (single
      photon emission computed tomography) images of the brain.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2000</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Ratio of the Specific Striatal [123I]B-CIT Uptake to the Nondisplaceable Striatal [123I]B-CIT Uptake Between the Two Images</measure>
    <time_frame>40 weeks</time_frame>
    <description>The use of SPECT to measure striatal dopamine-transporter density with the use of [123I]B-CIT. Subjects underwent SPECT imaging just before the baseline visit and then again before the visit at week 40.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">142</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Assess [123I]B-CIT SPECT imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>To assess[123I]B-CIT SPECT imaging in early Parkinson's disease subjects on placebo compared to early verses later Levodopa. Subjects on Levodopa 150mg/day, Levodopa 300 mg/day, and Levodopa 600 mg/day will be assessed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[123I]B-CIT SPECT imaging</intervention_name>
    <description>To assess [123I]B-CIT SPECT imaging</description>
    <arm_group_label>Assess [123I]B-CIT SPECT imaging</arm_group_label>
    <other_name>[123I]B-CIT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Prior participation in the study titled Dopamine Transporter Imaging Assessment of
             Parkinson's Disease Progression (DAMD17-99-1-9472) [123I] B-CIT and Spect in Vivo
             Imaging Assessment of Dopamine Transporter Density in Subjects With Early Parkinson's
             Disease Participating in Earlier Vs. Later Levodopa in Parkinson's Disease (ELLDOPA)].

        Exclusion Criteria:

          -  Inability to sign informed consent and participate in all study procedures.

          -  Mini mental status exam &lt; 25.

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth L Marek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute for Neurodegenerative Disorders</affiliation>
  </overall_official>
  <link>
    <url>http://www.indd.org</url>
    <description>Institute for Neurodegenerative Disorders</description>
  </link>
  <results_reference>
    <citation>Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K; Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004 Dec 9;351(24):2498-508.</citation>
    <PMID>15590952</PMID>
  </results_reference>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2005</study_first_submitted>
  <study_first_submitted_qc>August 23, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 25, 2005</study_first_posted>
  <results_first_submitted>October 7, 2010</results_first_submitted>
  <results_first_submitted_qc>July 15, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 8, 2014</results_first_posted>
  <last_update_submitted>July 15, 2014</last_update_submitted>
  <last_update_submitted_qc>July 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Institute for Neurodegenerative Disorders</investigator_affiliation>
    <investigator_full_name>Kenneth Marek, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>parkinson</keyword>
  <keyword>brain imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Dopamine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Placebo group</description>
        </group>
        <group group_id="P2">
          <title>Levodopa 150mg/Day</title>
          <description>Levodopa 150mg/day, [123I]ß-CIT and SPECT imaging</description>
        </group>
        <group group_id="P3">
          <title>Levodopa 300 mg/Day</title>
          <description>Levodopa 300mg/day, [123I]ß-CIT and SPECT imaging</description>
        </group>
        <group group_id="P4">
          <title>Levodopa 600 mg/Day</title>
          <description>Levodopa 600/day, [123I]ß-CIT and SPECT imaging</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="36"/>
                <participants group_id="P3" count="35"/>
                <participants group_id="P4" count="37"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo Group</title>
          <description>Subjects on placebo</description>
        </group>
        <group group_id="B2">
          <title>Levodopa 150mg/Day</title>
          <description>Subjects on 150mg/day of Levodopa</description>
        </group>
        <group group_id="B3">
          <title>Levodopa 300 mg/Day</title>
          <description>Subjects on 300 mg/day of Levodopa</description>
        </group>
        <group group_id="B4">
          <title>Levodopa 600 mg/Day</title>
          <description>Subjects on Levodopa 600 mg/day</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
            <count group_id="B2" value="38"/>
            <count group_id="B3" value="37"/>
            <count group_id="B4" value="38"/>
            <count group_id="B5" value="142"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Age of Subject in Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.9" spread="10.5"/>
                    <measurement group_id="B2" value="64.5" spread="11.8"/>
                    <measurement group_id="B3" value="63.1" spread="10.2"/>
                    <measurement group_id="B4" value="62.3" spread="9.8"/>
                    <measurement group_id="B5" value="63.4" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in the Ratio of the Specific Striatal [123I]B-CIT Uptake to the Nondisplaceable Striatal [123I]B-CIT Uptake Between the Two Images</title>
        <description>The use of SPECT to measure striatal dopamine-transporter density with the use of [123I]B-CIT. Subjects underwent SPECT imaging just before the baseline visit and then again before the visit at week 40.</description>
        <time_frame>40 weeks</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Group</title>
            <description>Participants receiving placebo</description>
          </group>
          <group group_id="O2">
            <title>Levodopa</title>
            <description>Subjects on 150 mg/day of Levodopa</description>
          </group>
          <group group_id="O3">
            <title>Levodopa 2</title>
            <description>Subjects on 300 mg/day of Levodopa</description>
          </group>
          <group group_id="O4">
            <title>Levodopa 3</title>
            <description>Subjects on 600 mg/day of Levodopa</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Ratio of the Specific Striatal [123I]B-CIT Uptake to the Nondisplaceable Striatal [123I]B-CIT Uptake Between the Two Images</title>
          <description>The use of SPECT to measure striatal dopamine-transporter density with the use of [123I]B-CIT. Subjects underwent SPECT imaging just before the baseline visit and then again before the visit at week 40.</description>
          <population>Per protocol</population>
          <units>percent change of B-CIT Uptake</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="36"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>B-CIT Uptake</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="33"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="11.3"/>
                    <measurement group_id="O2" value="-4.7" spread="10.8"/>
                    <measurement group_id="O3" value="-3.7" spread="9.1"/>
                    <measurement group_id="O4" value="-6.9" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>I123BCIT</title>
          <description>[123I]ß CIT and SPECT imaging' .</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="142"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Principal Investigator</name_or_title>
      <organization>Institute for Neurodegenerative Disorders</organization>
      <phone>203 401 4300</phone>
      <email>kmarek@indd.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

